Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial
Peter Hillmen(Leeds Teaching Hospitals NHS Trust), Wojciech Jurczak(The Maria Sklodowska-Curie National Research Institute of Oncology), Meng Ji(Masaryk University), Susan O’Brien(University of California, Irvine), Adam Idoine, Nicole Lamanna(Memorial Sloan Kettering Cancer Center), Jennifer R. Brown(Dana-Farber Cancer Institute), Lugui Qiu(Chinese Academy of Medical Sciences & Peking Union Medical College), Tommi Salmi(Düsseldorf University Hospital), Andrzej Mital(Gdańsk Medical University), Habte Yimer(Texas Oncology), Alessandra Ferrajoli(The University of Texas MD Anderson Cancer Center), Peter Ganly(European Bioinformatics Institute), Constantine S. Tam(The Royal Melbourne Hospital), Jessica L. Yecies, Anders Österborg(Karolinska University Hospital), Keshu Zhou(Henan Cancer Hospital), Mazyar Shadman(University of Washington), Jiřı́ Mayer(University Hospital Brno), Amanda Gillespie-Twardy(Düsseldorf University Hospital), Sebastian Grosicki(Medical University of Silesia), Kenneth Wu(Düsseldorf University Hospital), Martin Šimkovič(Charles University), Tadeusz Robak(Medical University of Lodz), Barbara Eichhorst, Jane Huang, Maciej Kaźmierczak(Silesian University of Technology), Robert Weinkove(Malaghan Institute of Medical Research)
Cited by 93
Related Papers
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k